Chandler H. Park, MD

Chandler H. Park, MD, discusses real-world data for maintenance avelumab in bladder cancer and factors that sway his treatment selection.

Chandler H. Park, MD, discusses NCCN treatment regimens for patients with metastatic bladder cancer.

In the second article of this series, Chandler H. Park, MD, a genitourinary oncologist at Norton Cancer Institute, reviews recently updated data on advanced renal cell carcinoma treatments.

Chandler Park, MD shares clinical insights regarding care for patients with renal cell carcinoma, touching on treatment selection and managing adverse effects.

Thoughtful discussion of ongoing clinical trials in the renal cell carcinoma landscape, with a particular focus on their eventual clinical implications.

Chandler H. Park, MD, discusses the treatment landscape for advanced renal cell carcinoma and factors that influence treatment decisions.

An overview of the KEYNOTE-564 study design followed by an analysis of 30-month follow-up data presented at the 2022 ASCO Genitourinary Cancers Symposium.

Chandler Park, MD introduces a renal cell carcinoma (RCC) patient case, sharing his initial impressions and discussing treatment approaches.

In a 7 to 1 vote, oncologists favored the use of axitinib in combination with pembrolizumab or avelumab over cabozantinib monotherapy for the treatment of intermediate and high-risk clear cell renal cell carcinoma. Chandler H. Park, MD, reviewed that clinical trial research that supports the axitinib combinations, as well as other targeted therapy options.